Electronic Theses and Dissertation

Latar belakang: Kanker paru merupakan jenis kanker penyebab utama kematian pada pria dan Wanita dengan kanker. Kemoterapi menunjukkan berbagai jenis efek samping tergantung dengan farmakokinetik dan farmakodinamika obat. Efek samping hematologis adalah salah satu komplikasi yang paling umum terjadi akibat kemoterapi. Efek samping ini meliputi neutropenia, anemia, dan trombositopenia, yang semuanya dapat secara signifikan mempengaruhi toleransi pasien terhadap kemoterapi.
Tujuan: Mengetahui hubungan antara derajat efek samping hematologis terhadap respon kemoterapi pada pasien kanker paru
Metode: Penelitian analitik obervasional dengan desain potong lintang. Sampel penelitian merupakan pasien kanker paru yang dirawat inap di RSUD dr. Zainoel Abidin Banda Aceh pada Januari sampai dengan Desember 2024. Respon kemoterapi dinilai menggunakan penilaian menggunakan modalitas CT-Scan bernama Response Evaluation Criteria in Solid Tumours (RECIST). Data dianalisa dengan SPSS 24 menggunakan Uji Spearman.
Hasil: Penelitian ini menunjukkan bahwa derajat anemia tidak berhubungan dengan respon kemoterapi yang dinilai dengan RECIST (p=0,538), begitu pula pada variabel derajat neutropenia (p=0,207), leukopenia (p=0,983) dan Trombositopenia (p=0,798). Median hemoglobin, leukosit, neutrophil dan trombosit cenderung lebih rendah pada siklus ke 3 (hemoglobin 11,60 ± 1,78 g/dL vs 10,00 ± 1,72; leukosit 11.650/mm3 ± 3.514,25 ± 3.416,24/mm3 vs 6.290 ± 3.416,24/mm3; neutrofil 7.789,40 ± 3.379,48/μL vs 3.253,80 ± 2.991,51/μL dan trombosit 346.000 ± 132.898,37/µL vs 276.000 ± 136.109,81/µL.).
Kesimpulan: Pada penelitian ini diperoleh setiap efek samping kemoterapi tidak berhubungan terhadap respon kemoterapi berdasarkan RECIST. Marker Hematologis, baik hemoglobin, leukosit, neutrofil dan trombosit, menunjukkan penurunan pada siklus 3 dibandingkan pada siklus pertama.
Kata Kunci: Kanker Paru, Kemoterapi, Efek Samping Hematologis, RECIST

Background: Lung cancer is a leading cause of death in both men and women with cancer. Chemotherapy shows a variety of side effects depending on the pharmacokinetics and pharmacodynamics of the drugs. Hematological side effects are one of the most common complications arising from chemotherapy. These side effects include neutropenia, anemia, and thrombocytopenia, all of which can significantly affect patients' tolerance to chemotherapy. Objective: To determine the relationship between the degree of hematological side effects and chemotherapy respond in lung cancer patients. Methods: An analytical observational study with a cross-sectional design. The research sample consists of lung cancer patients hospitalized at the Dr. Zainoel Abidin Regional Hospital Banda Aceh from January to December 2024. Chemotherapy outcomes were assessed using a CT-Scan modality called Response Evaluation Criteria in Solid Tumours (RECIST). Data was analyzed using SPSS 24 with the Spearman test. Results: This study demonstrated that the degree of anemia was not associated with the chemotherapy response as assessed by RECIST (p = 0,538). Similarly, no significant associations were found for the degree of neutropenia (p = 0,207), leukopenia (p=0,983), or thrombocytopenia (p = 0,798). Median levels of hemoglobin, leukocytes, neutrophils, and platelets tended to be lower in the third chemotherapy cycle compared to the first (hemoglobin: 11,60 ± 1,78 g/dL vs. 10,00 ± 1,72 g/dL; leukocytes: 11.650/mm³ ± 3.514,25 vs. 6.290 ± 3.416,24/mm³; neutrophils: 7.789,40 ± 3.379,48/μL vs. 3.253,80 ± 2.991,51/μL; and platelets: 346.000 ± 132.898,37/μL vs. 276.000 ± 136.109,81/μL). Conclusion: In this study, none of the chemotherapy-related adverse effects were found to be associated with chemotherapy response based on RECIST criteria. Hematological markers, including hemoglobin, leukocytes, neutrophils, and platelets, showed a decline in the third cycle compared to the first cycle. Keywords: Lung Cancer, Chemotherapy, Hematology Side Effects, RECIST